Intravenous administration of epoetin in haemodialysis patients

EDTNA-ERCA Journal

Volumn 29, Issue 3, 2003, Pages 156-159

  De Vos, Jean Yves ^a   Upsing, Louise ^b  

^a Dialysis Unit   (Belgium)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Education; Erythropoietin administration and dosage; Injections, intravenous; Nurse; Renal dialysis

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ARTICLE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY DISEASE; NEEDLE; NURSE ATTITUDE; NURSE PATIENT RELATIONSHIP; PATIENT ATTITUDE; SYRINGE;

EID: 0042193482     PISSN: 1019083X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2003.tb00299.x     Document Type: Article

References (12)

1. Petersen J, Kang MS, Yeh I. The site of injection affects erythropoietin levels during dialysis. ASAIO Journal 1996; 42 (4): 263-265.
2. Foret JP. Diagnosing and treating anemia and iron deficiency in hemodialysis patients. Nephrology Nursing Journal 2002; 29 (3): 292-296.
3. De Schoenmakere G, Lameire N, Dhondt A, Van Loo A, Van der Goten J, Duym P, Vanholder R. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.). Nephrology Dialysis Transplantation 1998; 13 (7): 1770-1775.
4. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney International Supplement 1999; 69: S61-66.
5. Jensen JD, Madsen JK, Jensen LW. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin. European Journal of Clinical Pharmacology 1996; 50 (3): 171-177.
6. Taylor JE, Belch JJ, Fleming LW, Mactier RA, Henderson IS, Stewart WK. Erythropoietin response and route of administration. Clinical Nephrology 1994; 41 (5): 297-302.
7. Keen ML. Epoetin alfa-focus on dialyzability. Case study of the anemic patient. ANNA Journal 1995; 22 (6): 610-613.
8. Porter S. Human immune response to recombinant human proteins. Journal of Pharmacological Science 2001; 90 (1): 1-11.
9. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discovery 2002; 1 (6): 457-462.
10. Mori H, Hiraoka K, Yorifuji R, Iwasaki T, Gomikawa S, Inagaki O, Inoue S, Takamitsu Y, Fujita Y. Adsorption of human recombinant erythropoietin on dialysis membranes in vitro. Artificial Organs 1994; 18 (10): 725-728.
11. Gladziwa U, Klotz U, Baumer K, Zollinger R, Mann H, Sieberth HG. Pharmacokinetics of epoetin (recombinant human erythropoietin) after long term therapy in patients undergoing haemodialysis and haemofiltration. Clinical Pharmacokinet 1993; 25 (2): 145-153.
12. Petersen J, Kang MS, Hays MT Erythropoietin can be administered during dialysis. A kinetic analysis. ASAIO Journal 1996; 42 (1): 27-33.